Advanced search
Publication Cover
OncoImmunology Volume 8, 2019 - Issue 11
Submit an article Journal homepage
3,374
Views
29
CrossRef citations to date
0
Altmetric
Original Research

Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy

Deepak MittalImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QueenslandAustraliaView further author information
,
Dipti VijayanImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QueenslandAustraliaView further author information
,
Joost NeijssenGenmab, Utrecht, The NetherlandsView further author information
,
Joost KreijtzAduro Biotech Europe, Oss, The NetherlandsView further author information
,
Maurice M. J. M. HabrakenAduro Biotech Europe, Oss, The NetherlandsView further author information
,
Hans Van EenennaamAduro Biotech Europe, Oss, The NetherlandsView further author information
,
Andrea Van ElsasAduro Biotech Europe, Oss, The NetherlandsView further author information
&
Mark J. SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, QueenslandAustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7098-7240View further author information
ORCID Icon show all
Article: e1648171 | Received 16 Jun 2019, Accepted 23 Jul 2019, Published online: 26 Aug 2019

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jorge Cebada, Amira Flores, Cindy Bandala, Ian Lizaliturri-Flores, Nemesio Villa-Ruano & Martin Perez-Santos. (2020) Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054. Expert Opinion on Therapeutic Patents 30:7, pages 487-494.
Read now
Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer & Erika Vacchelli. (2020) Trial watch: IDO inhibitors in cancer therapy. OncoImmunology 9:1.
Read now

Articles from other publishers (27)

Paola Zagami, Luca Boscolo Bielo, Eleonora Nicolò & Giuseppe Curigliano. (2023) HER2-positive breast cancer: cotargeting to overcome treatment resistance. Current Opinion in Oncology 35:6, pages 461-471.
Crossref
Hao Chen, Yuhao Si, Jialiang Wen, Chunlei Hu, Erjie Xia, Yinghao Wang & Ouchen Wang. (2023) P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer. Neoplasia 43, pages 100913.
Crossref
Xiaoxue Wu, Shuting Huang, Weiling He & Mei Song. (2023) Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers. International Immunopharmacology 122, pages 110602.
Crossref
Anna Pous, Lucía Notario, Cinta Hierro, Laura Layos & Cristina Bugés. (2023) HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. International Journal of Molecular Sciences 24:14, pages 11403.
Crossref
Yi Cao, Yunjin Li, Ruijie Liu, Jianhua Zhou & Kuansong Wang. (2023) Preclinical and Basic Research Strategies for Overcoming Resistance to Targeted Therapies in HER2-Positive Breast Cancer. Cancers 15:9, pages 2568.
Crossref
María Florencia Mercogliano, Sofía Bruni, Florencia Luciana Mauro & Roxana Schillaci. (2023) Emerging Targeted Therapies for HER2-Positive Breast Cancer. Cancers 15:7, pages 1987.
Crossref
Noelia Silva-Pilipich, Ángela Covo-Vergara, Lucía Vanrell & Cristian Smerdou. 2023. Viral Vectors in Cancer Immunotherapy. Viral Vectors in Cancer Immunotherapy 43 86 .
Regina Padmanabhan, Hadeel Kheraldine, Ishita Gupta, Nader Meskin, Anas Hamad, Semir Vranic & Ala-Eddin Al Moustafa. (2022) Quantification of the growth suppression of HER2+ breast cancer colonies under the effect of trastuzumab and PD-1/PD-L1 inhibitor. Frontiers in Oncology 12.
Crossref
Gaia Griguolo, Anna Tosi, Maria Vittoria Dieci, Susan Fineberg, Valentina Rossi, Annavera Ventura, Michele Bottosso, Luc Bauchet, Federica Miglietta, Jack Jacob, Valerie Rigau, Matteo Fassan, William Jacot, PierFranco Conte, Antonio Rosato, Amelie Darlix & Valentina Guarneri. (2022) A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. Neuro-Oncology 24:12, pages 2146-2158.
Crossref
Adilai Aisa, Shanshan Weng, Xinyu Li, Ding Zhang & Ying Yuan. (2022) Immune checkpoint inhibitors combined with HER-2 targeted therapy in HER-2 positive gastroesophageal cancer. Critical Reviews in Oncology/Hematology 180, pages 103864.
Crossref
Xiaofan Wu, Hongjian Yang, Xingfei Yu & Jiang-Jiang Qin. (2022) Drug-resistant HER2-positive breast cancer: Molecular mechanisms and overcoming strategies. Frontiers in Pharmacology 13.
Crossref
Giulia Petroni, Aitziber Buqué, Lisa M. Coussens & Lorenzo Galluzzi. (2022) Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nature Reviews Drug Discovery 21:6, pages 440-462.
Crossref
Chang-ling Gu, Hai-xia Zhu, Lan Deng, Xiao-qing Meng, Kai Li, Wei Xu, Le Zhao, Yue-qin Liu, Zhen-ping Zhu & Hao-min Huang. (2021) Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition. Acta Pharmacologica Sinica 43:3, pages 672-680.
Crossref
Fabien Thoreau & Vijay Chudasama. (2022) Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology 3:2, pages 140-169.
Crossref
Evanthia T. Roussos Torres & Leisha A. Emens. (2021) Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies. Breast Cancer Research and Treatment 191:2, pages 291-302.
Crossref
Pablo Mandó, Sergio G. Rivero, Manglio M. Rizzo, Marina Pinkasz & Estrella M. Levy. (2021) Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era. The Breast 60, pages 15-25.
Crossref
Mei-Hua Jin, Ah-Rong Nam, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Jae-Min Kim, Jeesun Yoon, Tae-Yong Kim & Do-Youn Oh. (2021) WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Cancer 24:5, pages 1003-1020.
Crossref
Qi Wang, Kankana Bardhan, Vassiliki A. Boussiotis & Nikolaos Patsoukis. (2021) The PD‐1 Interactome. Advanced Biology 5:9.
Crossref
Lun Li, Min Chen, Shuyue Zheng, Hanlu Li, Weiru Chi, Bingqiu Xiu, Qi Zhang, Jianjing Hou, Jia Wang & Jiong Wu. (2021) Clinical and Genetic Predictive Models for the Prediction of Pathological Complete Response to Optimize the Effectiveness for Trastuzumab Based Chemotherapy. Frontiers in Oncology 11.
Crossref
Semir Vranic, Farhan S. Cyprian, Zoran Gatalica & Juan Palazzo. (2021) PD-L1 status in breast cancer: Current view and perspectives. Seminars in Cancer Biology 72, pages 146-154.
Crossref
Mobina Jalalvand, Farzaneh Darbeheshti & Nima Rezaei. (2021) Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer. Immunotherapy 13:7, pages 587-603.
Crossref
Renske J. E. van den Bijgaart, Fabian Schuurmans, Jurgen J. Fütterer, Marcel Verheij, Lenneke A. M. Cornelissen & Gosse J. Adema. (2021) Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ. Frontiers in Immunology 12.
Crossref
Giulia Petroni, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2021) Immunomodulation by targeted anticancer agents. Cancer Cell 39:3, pages 310-345.
Crossref
Mehdi Mohammadi, Mahmood Jeddi-Tehrani, Forough Golsaz-Shirazi, Mohammad Arjmand, Tannaz Bahadori, Mohammad Ali Judaki, Fariba Shiravi, Hengameh Ahmadi Zare, Farzaneh Notash Haghighat, Maryam Mobini, Mohammad Mehdi Amiri & Fazel Shokri. (2021) A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects In Vitro and In Vivo. Frontiers in Immunology 11.
Crossref
Ting Yang, Ziyi Fu, Yin Zhang, Min Wang, Changfei Mao & Weihong Ge. (2020) Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer. Biomedicine & Pharmacotherapy 129, pages 110465.
Crossref
Antonino Musolino, Daniela Boggiani, Benedetta Pellegrino, Daniele Zanoni, Angelica Sikokis, Gabriele Missale, Enrico Maria Silini, Giuseppe Maglietta, Antonio Frassoldati & Maria Michiara. (2020) Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer. Critical Reviews in Oncology/Hematology 149, pages 102927.
Crossref
Regina Padmanabhan, Hadeel Shafeeq Kheraldine, Nader Meskin, Semir Vranic & Ala-Eddin Al Moustafa. (2020) Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models. Cancers 12:3, pages 636.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.